LXLiyi Xu

Liyi Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liyi Xu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin

    by Arijit Ghosh, Wangqu Liu, Ling Li, Gayatri J. Pahapale, Si Young Choi, Liyi Xu, Qi Huang, Ruili Zhang, Zijian Zhong, Florin M. Selaru, et al.

    The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging as these drugs display low stability as well as poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that are deployed in the GI tract, then efficiently penetrate the GI mucosa to deliver a macromolecular drug, insulin, to the systemic circulation. We performed in vitro studies to characterize insulin release and assess the penetration capability of microinjectors and we measured the in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin transmucosally to the systemic circulation at levels similar to those with intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these microinjectors will significantly advance drug delivery across the GI tract mucosa to the systemic circulation in a safe manner.


  • Open Access

    Autonomous untethered microinjectors for gastrointestinal delivery of insulin

    by Arijit Ghosh, Wangqu Liu, Ling Li, Gayatri Pahapale, Si Young Choi, Liyi Xu, Qi Huang, Florin M. Selaru, David H. Gracias

    The delivery of macromolecular drugs via the gastrointestinal (GI) tract is challenging. Macromolecular drugs display low stability and poor absorption across the intestinal epithelium. While permeation-enhancing drug delivery methods can increase the bioavailability of low molecular weight drugs, the effective delivery of high molecular weight drugs across the tight epithelial cell junctions remains a formidable challenge. Here, we describe autonomous microinjectors that can efficiently penetrate the GI mucosa and deliver insulin systemically. In addition, we performed in vitro studies to characterize insulin release and the penetration capacity of microinjectors and measure in vivo release of insulin in live rats. We found that the microinjectors administered within the luminal GI tract could deliver insulin trans-mucosally to the systemic circulation at similar levels to intravenously administered insulin. Due to their small size, tunability in sizing and dosing, wafer-scale fabrication, and parallel, autonomous operation, we anticipate that these novel microinjectors could significantly advance drug delivery across the GI tract mucosa to the systemic circulation.

  • Open Access

    Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo

    by Arijit Ghosh, Ling Li, Liyi Xu, Ranjeet P. Dash, Neha Gupta, Jenny Lam, Qianru Jin, Venkata Akshintala, Gayatri Pahapale, Wangqu Liu, et al.

    Hookworm inspired, autonomous latching on the gastrointestinal mucosa extends the in vivo retention of a drug delivery device.